Literature DB >> 19835956

Transgenic models for cytokine-induced neurological disease.

Iain L Campbell1, Markus J Hofer, Axel Pagenstecher.   

Abstract

Considerable evidence supports the idea that cytokines are important mediators of pathophysiologic processes within the central nervous system (CNS). Numerous studies have documented the increased production of various cytokines in the human CNS in a variety of neurological and neuropsychiatric disorders. Deciphering cytokine actions in the intact CNS has important implications for our understanding of the pathogenesis and treatment of these disorders. One approach to address this problem that has been used widely employs transgenic mice with CNS-targeted production of different cytokines. Transgenic production of cytokines in the CNS of mice allows not only for the investigation of complex cellular responses at a localized level in the intact brain but also more closely recapitulates the expression of these mediators as found in disease states. As discussed in this review, the findings show that these transgenic animals exhibit wide-ranging structural and functional deficits that are linked to the development of distinct neuroinflammatory responses which are relatively specific for each cytokine. These cytokine-induced alterations often recapitulate those found in various human neurological disorders not only underscoring the relevance of these models but also reinforcing the clinicopathogenetic significance of cytokines in diseases of the CNS.
Copyright © 2009 Elsevier B.V. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19835956      PMCID: PMC2888861          DOI: 10.1016/j.bbadis.2009.10.004

Source DB:  PubMed          Journal:  Biochim Biophys Acta        ISSN: 0006-3002


  184 in total

1.  Regulation of neuronal Bcl2 protein expression and calcium homeostasis by transforming growth factor type beta confers wide-ranging protection on rat hippocampal neurons.

Authors:  J H Prehn; V P Bindokas; C J Marcuccilli; S Krajewski; J C Reed; R J Miller
Journal:  Proc Natl Acad Sci U S A       Date:  1994-12-20       Impact factor: 11.205

2.  Expression of MRP14, 27E10, interferon-alpha and leukocyte common antigen by reactive microglia in postmortem human brain tissue.

Authors:  H Akiyama; K Ikeda; M Katoh; E G McGeer; P L McGeer
Journal:  J Neuroimmunol       Date:  1994-03       Impact factor: 3.478

Review 3.  gp120 as an etiologic agent for NeuroAIDS: neurotoxicity and model systems.

Authors:  D E Brenneman; S K McCune; R F Mervis; J M Hill
Journal:  Adv Neuroimmunol       Date:  1994

Review 4.  Cytokine therapeutics: lessons from interferon alpha.

Authors:  J U Gutterman
Journal:  Proc Natl Acad Sci U S A       Date:  1994-02-15       Impact factor: 11.205

Review 5.  Regulation of pituitary ACTH secretion during chronic stress.

Authors:  G Aguilera
Journal:  Front Neuroendocrinol       Date:  1994-12       Impact factor: 8.606

6.  Elevation of transforming growth factor-beta 1 level in cerebrospinal fluid of patients with communicating hydrocephalus after subarachnoid hemorrhage.

Authors:  K Kitazawa; T Tada
Journal:  Stroke       Date:  1994-07       Impact factor: 7.914

7.  Induction of communicating hydrocephalus in mice by intrathecal injection of human recombinant transforming growth factor-beta 1.

Authors:  T Tada; M Kanaji; S Kobayashi
Journal:  J Neuroimmunol       Date:  1994-03       Impact factor: 3.478

8.  Site-specific hippocampal pathophysiology due to cerebral overexpression of interleukin-6 in transgenic mice.

Authors:  S C Steffensen; I L Campbell; S J Henriksen
Journal:  Brain Res       Date:  1994-07-25       Impact factor: 3.252

9.  Functional role of type I and type II interferons in antiviral defense.

Authors:  U Müller; U Steinhoff; L F Reis; S Hemmi; J Pavlovic; R M Zinkernagel; M Aguet
Journal:  Science       Date:  1994-06-24       Impact factor: 47.728

10.  Influence of infection on exacerbations of multiple sclerosis.

Authors:  H S Panitch
Journal:  Ann Neurol       Date:  1994       Impact factor: 10.422

View more
  17 in total

1.  Neurotropic viral infections leading to epilepsy: focus on Theiler's murine encephalomyelitis virus.

Authors:  Jane E Libbey; Robert S Fujinami
Journal:  Future Virol       Date:  2011-11       Impact factor: 1.831

2.  IL-17A Promotes Granulocyte Infiltration, Myelin Loss, Microglia Activation, and Behavioral Deficits During Cuprizone-Induced Demyelination.

Authors:  Julian Zimmermann; Michael Emrich; Marius Krauthausen; Simon Saxe; Louisa Nitsch; Michael T Heneka; Iain L Campbell; Marcus Müller
Journal:  Mol Neurobiol       Date:  2017-01-13       Impact factor: 5.590

Review 3.  Immunoinflammatory diseases of the central nervous system - the tale of two cytokines.

Authors:  M J Hofer; I L Campbell
Journal:  Br J Pharmacol       Date:  2015-06-12       Impact factor: 8.739

Review 4.  How and why do T cells and their derived cytokines affect the injured and healthy brain?

Authors:  Anthony J Filiano; Sachin P Gadani; Jonathan Kipnis
Journal:  Nat Rev Neurosci       Date:  2017-04-27       Impact factor: 34.870

5.  Systemic inflammation as a predictor of brain aging: Contributions of physical activity, metabolic risk, and genetic risk.

Authors:  Fabian Corlier; George Hafzalla; Joshua Faskowitz; Lewis H Kuller; James T Becker; Oscar L Lopez; Paul M Thompson; Meredith N Braskie
Journal:  Neuroimage       Date:  2018-01-28       Impact factor: 6.556

6.  Trans-signaling is a dominant mechanism for the pathogenic actions of interleukin-6 in the brain.

Authors:  Iain L Campbell; Maria Erta; Sue Ling Lim; Ricardo Frausto; Ulrike May; Stefan Rose-John; Jürgen Scheller; Juan Hidalgo
Journal:  J Neurosci       Date:  2014-02-12       Impact factor: 6.167

7.  Neurobiology of vascular dementia.

Authors:  Ana-Maria Enciu; Stefan N Constantinescu; Laurenţiu M Popescu; Dafin F Mureşanu; Bogdan O Popescu
Journal:  J Aging Res       Date:  2011-08-17

8.  CNS-targeted production of IL-17A induces glial activation, microvascular pathology and enhances the neuroinflammatory response to systemic endotoxemia.

Authors:  Julian Zimmermann; Marius Krauthausen; Markus J Hofer; Michael T Heneka; Iain L Campbell; Marcus Müller
Journal:  PLoS One       Date:  2013-02-27       Impact factor: 3.240

9.  Repurposing of Secukinumab as Neuroprotective in Cuprizone-Induced Multiple Sclerosis Experimental Model via Inhibition of Oxidative, Inflammatory, and Neurodegenerative Signaling.

Authors:  Amany El-Shahawy Abdel-Maged; Amany M Gad; Laila Ahmed Rashed; Samar S Azab; Eman A Mohamed; Azza S Awad
Journal:  Mol Neurobiol       Date:  2020-06-08       Impact factor: 5.682

10.  Astrocyte regulation of CNS inflammation and remyelination.

Authors:  Kumiko I Claycomb; Kasey M Johnson; Paige N Winokur; Anthony V Sacino; Stephen J Crocker
Journal:  Brain Sci       Date:  2013-07-22
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.